| |
| |
|
| Insider
Information: |
Morrison Briggs |
| Relationship: |
Director |
| City: |
Waltham |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
102,091 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,476,723 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
102,091 |
|
|
| Total
Value |
$1,476,723 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
7
|
|
Stock
price went up :
|
2
|
4
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
2.0
|
1.3
|
| Percentage
Gain/Loss : |
 52.4%
|
 -14.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Syndax Pharmaceuticals Inc |
SNDX |
|
2024-02-07 |
34,836 |
|
0 |
Premium* |
|
|
Arvinas Holding Company, Llc |
ARVN |
Director |
2024-05-29 |
29,996 |
|
0 |
Premium* |
|
|
Repare Therapeutics Inc. |
RPTX |
Director |
2020-06-23 |
4,800 |
2020-06-23 |
0 |
Premium* |
|
|
Codiak Biosciences, Inc. |
CDAK |
Director |
2021-02-17 |
4,761 |
2021-02-17 |
0 |
Premium* |
|
|
Werewolf Therapeutics, Inc. |
HOWL |
Director |
2021-04-29 |
15,523 |
|
0 |
Premium* |
|
|
Carisma Therapeutics Inc |
CARM |
Director |
2023-03-07 |
12,175 |
2023-03-07 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
58 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2021-02-08 |
4 |
OE |
$7.20 |
$253,123 |
D/D |
35,156 |
83,492 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2021-12-17 |
4 |
OE |
$10.90 |
$383,200 |
D/D |
35,156 |
83,492 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2022-09-15 |
4 |
OE |
$7.20 |
$480,780 |
D/D |
66,775 |
84,611 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2022-04-01 |
4 |
OE |
$10.90 |
$768,941 |
D/D |
70,545 |
88,381 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2022-09-14 |
4 |
OE |
$7.20 |
$631,044 |
D/D |
87,645 |
105,481 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2020-11-09 |
4 |
OE |
$7.20 |
$453,154 |
D/D |
62,938 |
109,503 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2021-09-17 |
4 |
OE |
$7.20 |
$505,886 |
D/D |
70,262 |
118,598 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
• • – |
2022-09-19 |
4 |
OE |
$10.90 |
$1,246,295 |
D/D |
114,339 |
132,175 |
0 |
- |
|
58 Records found
|
|
Page 3 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
